SavedAdd your journal

Journals / Turkish Journal of Pharmaceutical Sciences / 2004 / Cilt: 1 - Sayı: 1

1-[(2-aminofenil)tiyo]-1-fenil-2-nitroalkan türevlerinin Helicobacter pylori'ye karşı aktiviteleri

Activity of 1-[(2-aminophenyl)thio]-1-phenyl-2-nitroalkane derivatives against Helicobacter pylori

Mehtap GÖKÇE
BERRİN ÖZÇELİK
Yakut AKYÖN
Erdoğan BERÇİN
Ningur NOYANALPAN
Pages
55–64
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to the results anti-Helicobacter pylori activities of the compounds are not close to that of ampicillin and ofloxazin.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, anti-Helicobacter pylori activity of previously synthesized l-[(2-aminophenyl)thio]-l-phenyl-2-nitroethane 1 and l-[(2-aininophenyl)thio]-J-phenyl-2-nitropropane 2 derivatives has been examined.
📊
Key Findings & Data:Anti-Helicobacter pylori activity of these compounds was investigated in-vitro agar dilution method.
💡
Conclusion & Impact:According to the results anti-Helicobacter pylori activities of the compounds are not close to that of ampicillin and ofloxazin.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Stirenler · Helicobacter pylori · Styrenes

Abstract

In this study, anti-Helicobacter pylori activity of previously synthesized l-[(2-aminophenyl)thio]-l-phenyl-2-nitroethane 1 and l-[(2-aininophenyl)thio]-J-phenyl-2-nitropropane 2 derivatives has been examined. Anti-Helicobacter pylori activity of these compounds was investigated in-vitro agar dilution method. Ampicillin and ofloxazin were used as references. According to the results anti-Helicobacter pylori activities of the compounds are not close to that of ampicillin and ofloxazin. However, compound lb was found as having a comparable activity to reference compounds.

Özet

Bu çalışmada sentezleri daha önceden yapılan 1 -[(2-aminofenil)tiyo]-1 -fenil-2-nitroetan 1 ve l-[(2-aminofenil)tiyo]-l-fenil-2-nitropropan 2 türevlerinin anti-Helicobacter pylori aktiviteleri test edilmiştir. Bileşiklerin anti-Helicobacter pylori aktiviteleri in-vitro agar dilution metodu ile araştırılmıştır. Ampisilin ve ofloksazin referans bileşikler olarak kullanılmıştır. Sonuçlara göre bileşiklerin anti-Helicobacter pylori aktivitesi ampisilin ve ofloksazine yakın değildir. Buna rağmen lb bileşiği referans bileşiklerle kıyaslanabilir aktiviteye sahip bulunmuştur.

🔖

Cite This Article

GÖKÇE, M., ÖZÇELİK, B., AKYÖN, Y., BERÇİN, E., NOYANALPAN, N. (2004). 1-[(2-aminofenil)tiyo]-1-fenil-2-nitroalkan türevlerinin Helicobacter pylori'ye karşı aktiviteleri. Turkish Journal of Pharmaceutical Sciences, Cilt: 1 - Sayı: 1, 55–64. https://ajindex.com/articles/403902

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Malfertheiner P., Megraud F., Micetti P., Price A., "The Year in Helicobacter pylori" (1994); Current Science Ltd: London, 1994
  2. Tytgat G. N J., "Review in Depth. Helicobacter pylori: Recent development" Eur. J.Gastroenterol. Hepatol, 7, 289-321, 1995
  3. Warren J. R., Marshall B. J. "Unidentified Curved bacilli in the stomach of patients with gastritis and peptic ulceration" Lancet, 1311-1315, 1984
  4. B. J. Marshall, "Helicobacter pylory", Am. J. Gastroenterol., 89, 116-128, 1994
  5. Alper J., "Ulcer as an infectious disease" Science 260, 159-160, 1993 6. Heatley R. V., "The treatment of Helicobacter pylori infection" Aliment Pharmacol. Tlier.6, 291-303, 1992
  6. Chiba N., Rao B. V., Rademaker J. W., Hunt R. H., "Metaanalysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori" Am. j. Gastroenterol., 87, 1716-1727,1992
  7. Dooley C. P., "Helicobacter pylori review of search findings" Aliment Pharmacol Tlier., 5 129-143,1991
  8. Tytgat G. N J., Lee A.,.Graham D. Y, Dixon M. F., Rokkas T., "The role of infectious agents in peptic ulcer diasease" G astro enter ol. Int., 6, 76-89, 1993
  9. Ateshkadi A., Lam N. P., Johnson C. A., "Helicobacter pylori and peptic ulcer disease"Clin. Pharm., 12, 34.-38, 1993
  10. Fletcher P. J., Craig Q. M., "The role and treatment of Helicobacter pylori infection in peptic ulcer disease: a rewiew of the relationship between Helicobacter pylori infection and peptic ulcer disease"/. Clin. Pharm. Ther., 18, 311-316, 1993
  11. Kiihler T. C, Swanson ML, Christenson B., Klintenber G. C. A., Lamm B., Fagerhag J., Roberto G., Olwegard-Halvarsson ML, Shcherbuchin V., Elebring T., Sjöström J.E., "Novel Structures derived from 2-[[(2-pyridyl)methyl]thio]-l-lH-benzimidazole as anti-helicobacter pylory agents" J.Med. Chem., 45, 4282-4299,2002
  12. Yoshida Y., Matsuda K., Sasaki H., Matsumoto Y., Matsumoto S., Takasugi H."Synthesis and anh-helicobacterpylory activity of FR182024, a new cephem derivative" Bioorganic & Medicinal Chemistry Letters, 9, 3123-3126, 1999
  13. Yoshida Y., Matsuda K., Sasaki II., Matsumoto Y., Matsumoto S., Tawara S.,Takasugi H., " Studies on anti-Helicobacter pylori agents. Part 2: New cephem derivatives", Bioorganic & Medicinal Chemistry Letters 8, 2317-2335, 2000
  14. NIH concessus development panel on Helicobacter pylori in peptic ulcer disease,J. Am. Med. Assoc, 272, 65-69,1994
  15. Partipilio M. L, Woster P. S., "The Role of Helicobacter pylori in peptic ulcer disease"Pharmacotherap